NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

NTC

More Like This

PR Newswire associated0

NTC Launches Imperial, the new eye drops product line on THE PATIENT'S SIDE

PR Newswire associated0

NTC gives long term consistency to its ophtha portfolio with another MDR CE Certificate approval

PR Newswire associated0

NTC Ophthalmics lberica: Young ophthalmologists square in Zahara Los Atunes

Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution)

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease (Graphic: Business Wire)

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease

New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection

PR Newswire associated0

Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024